Abstract
Atrial fibrillation (AF) is a common arrhythmia in clinical practice. An important component of the management of patients with AF involves prevention of thromboembolism and stroke. Coumarins, such as warfarin had been the only available oral antithrombotic agent for prevention of thromboembolism for many decades. Following intestinal absorption, coumarins inhibit multiple steps of the clotting cascade that leads to inhibition of coagulation factors II, VII, IX and X. In addition to delayed and variable inhibition of coagulation, coumarin therapy has a narrow therapeutic window for optimal balance of risk and benefit, which requires regular assessment of the international normalized ratio (INR) to monitor coagulation. A quest for safer, more effective therapies that do not need monitoring has led to the development of dabigatran, rivaroxaban, and apixaban. In this article, we review these newer antithrombotic agents and discuss role of these drugs in clinical practice.
Keywords: Atrial fibrillation, Antithrombotic, Bleeding, Thromboembolism, Stroke, Clotting factors, embolism, antagonists, intracranial hemorrhage
Cardiovascular & Hematological Disorders-Drug Targets
Title:Antithrombotic Options for Atrial Fibrillation in 2012
Volume: 12 Issue: 1
Author(s): Jennifer Rude, Karla Quevedo, Lissette Rodriguez de Armas and Debabrata Mukherjee
Affiliation:
Keywords: Atrial fibrillation, Antithrombotic, Bleeding, Thromboembolism, Stroke, Clotting factors, embolism, antagonists, intracranial hemorrhage
Abstract: Atrial fibrillation (AF) is a common arrhythmia in clinical practice. An important component of the management of patients with AF involves prevention of thromboembolism and stroke. Coumarins, such as warfarin had been the only available oral antithrombotic agent for prevention of thromboembolism for many decades. Following intestinal absorption, coumarins inhibit multiple steps of the clotting cascade that leads to inhibition of coagulation factors II, VII, IX and X. In addition to delayed and variable inhibition of coagulation, coumarin therapy has a narrow therapeutic window for optimal balance of risk and benefit, which requires regular assessment of the international normalized ratio (INR) to monitor coagulation. A quest for safer, more effective therapies that do not need monitoring has led to the development of dabigatran, rivaroxaban, and apixaban. In this article, we review these newer antithrombotic agents and discuss role of these drugs in clinical practice.
Export Options
About this article
Cite this article as:
Rude Jennifer, Quevedo Karla, Rodriguez de Armas Lissette and Mukherjee Debabrata, Antithrombotic Options for Atrial Fibrillation in 2012, Cardiovascular & Hematological Disorders-Drug Targets 2012; 12 (1) . https://dx.doi.org/10.2174/187152912801823110
DOI https://dx.doi.org/10.2174/187152912801823110 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Utilities of Pediatric Cardiac Catheterization
Current Cardiology Reviews Cathepsin D as a Promising Target for the Discovery of Novel Anticancer Agents
Current Cancer Drug Targets Beta-2 Agonists in Asthma: Medicine or Murderer?
Current Respiratory Medicine Reviews Management and Treatment of Cardiovascular Diseases in the Elderly
Current Pharmacogenomics and Personalized Medicine Synthesis and Biological Activity of N-(arylsulfonyl) Valine Hydrazones and Assistance of NMR Spectroscopy for Definitive 3D Structure
Letters in Drug Design & Discovery Phase 4 Studies in Heart Failure - What is Done and What is Needed?
Current Cardiology Reviews Human Ghrelin: A Gastric Hormone with Cardiovascular Properties
Current Pharmaceutical Design Cytotoxic Properties of Clofibrate and other Peroxisome Proliferators: Relevance to Cancer Progression
Current Medicinal Chemistry High-Throughput Structural Biology in Drug Discovery: Protein Kinases
Current Pharmaceutical Design Angiotensin-Converting Enzyme 2 Roles in the Pathogenesis of COVID-19
Current Hypertension Reviews Perioperative Heart-Brain Axis Protection in Obese Surgical Patients: The Nutrigenomic Approach
Current Medicinal Chemistry Drug Disposition in Pathophysiological Conditions
Current Drug Metabolism Are Calcium Channel Blockers First-Line Drugs for the Treatment of Hypertension and Cardiovascular Disease?
Current Hypertension Reviews Cardiovascular Effects of Ghrelin and Growth Hormone Secretagogues
Cardiovascular & Hematological Disorders-Drug Targets Effect of Simvastatin use on Autonomic Function in Patients with End Stage Renal Disease
Cardiovascular & Hematological Disorders-Drug Targets First Autochthonous case of Emerged Zoonotic Cutaneous Leishmaniasis in Mazandaran Province, Northern Iran: kDNA-PCR Evidence Base
Infectious Disorders - Drug Targets Contrast Medium Induced Nephropathy: New Insights into Prevention and Risk Management
Cardiovascular & Hematological Agents in Medicinal Chemistry Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies Oxidative Stress-Induced Ischemic Heart Disease: Protection by Antioxidants
Current Medicinal Chemistry The Role of Calcium Handling Mechanisms in Reperfusion Injury
Current Pharmaceutical Design